Heartflow has secured a new FDA clearance for its artificial intelligence program to analyze the buildup of dangerous plaques ...

Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...

While the average earnout potential per biopharma deal has declined over the last five years, the mean upfront value has been ...

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of ...

When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that ...

Medtronic has announced plans to double the footprint of its London office, focused on developing artificial intelligence and ...

The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.

When Roche unveiled its long-awaited obesity strategy yesterday, it included a b | Roche’s head of metabolic product development said the company is firing “on full cylinders” to get a phase 3 trial ...

Glooko is looking to expand its diabetes treatment platforms to the inpatient setting, with a plan to acquire Monarch Medical ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate ...

Though supported by Big Pharmas like Sanofi and Novo Nordisk parent company Novo Holdings, MapLight has readily burned through heaps of cash. The biotech’s current deficit is $251.6 million as of June ...